Overview

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2009-08-13
Target enrollment:
Participant gender:
Summary
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis